Risedronate Sodium
Brand Names: Actonel, Atelvia
Methodology & AI Transparency ⓘ
Risedronate Sodium Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Risedronate sodium tablets are a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis (1.1) Treatment to increase bone mass in men with osteoporosis (1.2) Treatment and prevention of glucocorticoid-induced osteoporosis (1.3) Treatment of Paget’s disease (1.4) Limitations of Use Optimal duration of use has not been determined.
- 2 Real-world patient consensus: 91% patient "Worth It" rating across 11 anonymous logs for Risedronate Sodium (RxNorm 905024).
- 3 Typical cash cost range: Public pharmacy ledger: $7.79 low cash benchmark vs. $34.50 chain retail average ($81.8555/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Risedronate Sodium): abdominal discomfort (3.8%), cutaneous rash (2.9%), dyspepsia (6%).
Ask our AI Specialists anything about Risedronate Sodium
Risedronate Sodium Mechanism, CYP450 Pathways & DailyMed Monograph
Risedronate sodium tablets are a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis (1.1) Treatment to increase bone mass in men with osteoporosis (1.2) Treatment and prevention of glucocorticoid-induced osteoporosis (1.3) Treatment of Paget’s disease (1.4) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.5 ) 1.1 Postmenopausal Osteoporosis Risedronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women.
12.1 Mechanism of Action Risedronate has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent. At the cellular level, risedronate inhibits osteoclasts. The osteoclasts adhere normally to the bone surface, but show evidence of reduced active resorption (for example, lack of ruffled border). Histomorphometry in rats, dogs, and minipigs showed that risedronate treatment reduces bone turnover (activation frequency, that is, the rate at which bone remodeling sites are activated) and bone resorption at remodeling sites.
Systemic exposure to Risedronate Sodium reflects Systemic oral bioavailability of roughly 76%–88% following first-pass transit absorption kinetics and hepatic enzymatic processing and renal clearance proportional to creatinine clearance (risedronate sodium), sustaining receptor engagement across a Biphasic clearance with 5–13 hr terminal t½ under Risedronate Sodium maintenance half-life window (initial pharmacodynamic onset within 1–3 hrs (peak cmax) for risedronate sodium response profile).
Dosing protocols (30.1 mg/1 / 4.9 mg/1 Tablet, Film Coated or 30 mg/1 Tablet, Film Coated or 129 mg/1 / 21 mg/1 Tablet, Film Coated or 150 mg/1 Tablet, Film Coated or 35 mg/1 Tablet, Film Coated) balance efficacy (91.00% patient satisfaction across 11 logs) against headache (7.6% of reports), nausea (7.3% of reports), dyspepsia (6% of reports), with strict avoidance in known hypersensitivity to risedronate sodium or structurally related bisphosphonate compounds; concomitant contra-labeled cyp/transporter therapies during active risedronate sodium administration.
Chelation with aluminum, magnesium, calcium, or iron in the gut lumen can lower oral Risedronate Sodium absorption; stagger doses by 2–4 hours.
Avoid overlapping bisphosphonate prescriptions alongside Risedronate Sodium to prevent cumulative receptor toxicity.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Risedronate Sodium or structurally related bisphosphonate compounds
- Concomitant contra-labeled CYP/transporter therapies during active Risedronate Sodium administration
Logged Side-Effect Incidence (11 Reports)
Risedronate Sodium Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Risedronate Sodium)
Human clinical trial evidence for Risedronate Sodium is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Risedronate Sodium Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $81.8555/unit (~$2455.66/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $7.79 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 11 Anonymous DotMD Community Micro-Logs | $8.96 / mo | View logs ↓ |
Risedronate Sodium Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Risedronate Sodium RxNorm Concept ID | 905024 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $81.8555 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $7.79 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 91.00% Worth It (11 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Risedronate Sodium Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Risedronate Sodium: FDA labeling (2026-02-11, NDC 65862-517), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Risedronate Sodium community threads and patient logs by age, biological sex, dosage, and treatment duration.